BRPI0706575B8 - uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado. - Google Patents

uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado.

Info

Publication number
BRPI0706575B8
BRPI0706575B8 BRPI0706575A BRPI0706575A BRPI0706575B8 BR PI0706575 B8 BRPI0706575 B8 BR PI0706575B8 BR PI0706575 A BRPI0706575 A BR PI0706575A BR PI0706575 A BRPI0706575 A BR PI0706575A BR PI0706575 B8 BRPI0706575 B8 BR PI0706575B8
Authority
BR
Brazil
Prior art keywords
collagen
type
autoimmune response
sample
lung
Prior art date
Application number
BRPI0706575A
Other languages
English (en)
Portuguese (pt)
Inventor
s wilkes David
J Klemsz Michael
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of BRPI0706575A2 publication Critical patent/BRPI0706575A2/pt
Publication of BRPI0706575B1 publication Critical patent/BRPI0706575B1/pt
Publication of BRPI0706575B8 publication Critical patent/BRPI0706575B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rehabilitation Therapy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
BRPI0706575A 2006-01-13 2007-01-13 uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado. BRPI0706575B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75919506P 2006-01-13 2006-01-13
US60/759195 2006-01-13
PCT/US2007/060533 WO2007120947A1 (en) 2006-01-13 2007-01-13 Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung

Publications (3)

Publication Number Publication Date
BRPI0706575A2 BRPI0706575A2 (pt) 2011-04-05
BRPI0706575B1 BRPI0706575B1 (pt) 2018-12-11
BRPI0706575B8 true BRPI0706575B8 (pt) 2021-05-25

Family

ID=38609836

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0706575A BRPI0706575B8 (pt) 2006-01-13 2007-01-13 uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado.

Country Status (8)

Country Link
US (3) US7759075B2 (cg-RX-API-DMAC7.html)
EP (2) EP1977234B1 (cg-RX-API-DMAC7.html)
JP (2) JP5030973B2 (cg-RX-API-DMAC7.html)
CN (1) CN101375157B (cg-RX-API-DMAC7.html)
AU (1) AU2007238533C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0706575B8 (cg-RX-API-DMAC7.html)
CA (2) CA2965211C (cg-RX-API-DMAC7.html)
WO (1) WO2007120947A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007238533C1 (en) * 2006-01-13 2013-08-15 Indiana University Research & Technology Corporation Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung
EP2120967B1 (en) * 2006-11-28 2015-10-21 University Of Southern California Method for promoting wound healing
EP2395996A1 (en) * 2009-02-13 2011-12-21 Indiana University Research and Technology Corporation Compounds and methods for inhibiting mmp2 and mmp9
CN107243076A (zh) * 2009-04-22 2017-10-13 印第安那大学科技研究公司 用于治疗慢性阻塞性肺病和哮喘的组合物和方法
DK2496720T3 (da) 2009-11-06 2020-09-28 Univ Leland Stanford Junior Ikke-invasiv diagnose af transplantatafstødning i organ-transplanterede patienter
US8481333B2 (en) * 2011-05-31 2013-07-09 Idexx Laboratories, Inc. Detection of degradation products of feline NT-proBNP
WO2013148232A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
JP6058354B2 (ja) * 2012-11-02 2017-01-11 東芝メディカルシステムズ株式会社 画像処理装置及び画像処理方法
JP6312054B2 (ja) * 2013-11-06 2018-04-18 学校法人日本大学 間質性肺炎のバイオマーカー
US20170082619A1 (en) 2015-09-23 2017-03-23 One Lambda, Inc. Methods of Detecting Alloantibodies Using HLA and Non-HLA Antigens

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
CA2055813A1 (en) 1990-11-20 1992-05-21 Dariush Davalian Cyclosporin immunoassay
US6911220B1 (en) 1992-02-19 2005-06-28 The General Hospital Corporation Allogeneic and xenogeneic transplantation
JP2702354B2 (ja) * 1992-05-11 1998-01-21 帝人株式会社 血中の肺組織障害マーカー
US5778875A (en) * 1996-05-06 1998-07-14 U.S. Divers Co., Inc. First stage regulator and rotatable in-line valve
AUPO026596A0 (en) * 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
US5962025A (en) 1996-07-16 1999-10-05 The University Of Tennessee Research Corporation Method for treatment of systemic sclerosis and related fibrotic diseases
US5990274A (en) 1997-11-25 1999-11-23 Dade Behring Inc. Cyclosporine derivatives and uses thereof
WO2001057089A1 (en) * 2000-01-31 2001-08-09 Asahi Kasei Kabushiki Kaisha Antibody for detecting chlamydia pneumoniae
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US7348005B2 (en) 2000-03-15 2008-03-25 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
HUP0300997A2 (hu) * 2000-03-23 2003-07-28 Akzo Nobel N.V. A MIA-fehérje alkalmazása immunterápiában
JP2002220343A (ja) * 2001-01-26 2002-08-09 Toray Ind Inc びまん性肺疾患延命剤
WO2005101018A1 (en) * 2004-04-08 2005-10-27 Janssen Pharmaceutica N.V. Immunohistochemical detection method of collagen in a tissue sample
WO2007059211A2 (en) 2005-11-16 2007-05-24 The University Of Tennessee Research Foundation Methods of treating fibrosing diseases by induction of immune tolerance
AU2007238533C1 (en) * 2006-01-13 2013-08-15 Indiana University Research & Technology Corporation Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung

Also Published As

Publication number Publication date
AU2007238533C1 (en) 2013-08-15
EP2672266A3 (en) 2014-02-05
CN101375157B (zh) 2015-06-17
US20110183356A1 (en) 2011-07-28
US20090017013A1 (en) 2009-01-15
CN101375157A (zh) 2009-02-25
JP5936349B2 (ja) 2016-06-22
US7939281B2 (en) 2011-05-10
BRPI0706575A2 (pt) 2011-04-05
EP1977234B1 (en) 2015-11-04
CA2641318A1 (en) 2007-10-25
EP1977234A1 (en) 2008-10-08
JP2009524023A (ja) 2009-06-25
US20110020838A1 (en) 2011-01-27
US7759075B2 (en) 2010-07-20
JP5030973B2 (ja) 2012-09-19
AU2007238533B2 (en) 2012-09-20
AU2007238533A1 (en) 2007-10-25
EP2672266B1 (en) 2018-08-01
WO2007120947A1 (en) 2007-10-25
EP1977234A4 (en) 2009-06-03
JP2012108137A (ja) 2012-06-07
CA2965211A1 (en) 2007-10-25
EP2672266A2 (en) 2013-12-11
CA2641318C (en) 2017-06-20
BRPI0706575B1 (pt) 2018-12-11
US8039225B2 (en) 2011-10-18
HK1126861A1 (en) 2009-09-11
CA2965211C (en) 2020-06-30

Similar Documents

Publication Publication Date Title
JP7849400B2 (ja) 外傷性脳損傷を診断及び査定するための、新規のバイオマーカー及び方法
Jaffar et al. Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis
EP1977234A4 (en) MOLECULES FOR THE TREATMENT OF PULMONARY DISEASE INVOLVING AN IMMUNE RESPONSE TO A CONNECTIVE TISSUE IN THE LUNG
BRPI0619748A8 (pt) anticorpo monoclonal, polinucleotídeo, região variável de cadeia leve, região variável de cadeia pesada, composição, mistura, métodos para produzir um anticorpo, para preparar uma composição farmacêutica ou uma mistura, de diagnóstico de uma doença ou condição associada a amilóide, para determinar o grau de carga de placa amiloidogênica em um tecido, para diagnosticar uma predisposição para uma doença ou condição, para monitorar doença residual mínima e para prever responsabilidade de um paciente, uso de um anticorpo monoclonal e/ou uma parte funcional do mesmo e/ou uma composição farmacêutica ou uma mistura, linhagem celular de hibridoma, e, kits de teste
BRPI0509419A (pt) método de ensaio imunossorvente ligado por enzimas, anticorpos, hibridoma e kit de imunoensaio
Wood et al. Accelerated onset of chronic wasting disease in elk (Cervus canadensis) vaccinated with a PrPSc-specific vaccine and housed in a prion contaminated environment
Lemberger et al. Comparison of urine protein profiles in cats without urinary tract disease and cats with idiopathic cystitis, bacterial urinary tract infection, or urolithiasis
Yang et al. IL-1β–dependent extravasation of preexisting lung-restricted autoantibodies during lung transplantation activates complement and mediates primary graft dysfunction
Sousse et al. Pulmonary histopathologic abnormalities and predictor variables in autopsies of burned pediatric patients
US20190041407A1 (en) Devices, systems and methods for quantifying hemoglobin s concentration
Park et al. Remote ischemic preconditioning in hemodialysis: a pilot study
Palladini et al. Diagnostic challenges of amyloidosis in Waldenström macroglobulinemia
BR112013030646A2 (pt) uso diagnóstico de pró-somatostatina
BR0115131A (pt) Teste de urina para a diagnose de doenças de priÈnio
WO2012165926A3 (ko) 항-atic 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
Bishop et al. Reference intervals for equine fecal calprotectin and calprotectin: protein ratio and preliminary clinical evaluation in horses with colic and colitis
CN118973710A (zh) 用于测定血液样品中的uch-l1、gfap和其他生物标志物的系统和方法
Bartsch et al. A novel approach to studying infective endocarditis: Ultrasound-guided wire injury and bacterial challenge in mice
Clarke Exploring the Role of Extracellular Vesicles in Equine Musculoskeletal Pathologies and Associated Regenerative Therapies
Wang et al. Muscle stem cell immunostaining
US20240067717A1 (en) Diagnosis and treatment of primary graft dysfunction following lung transplant
Fragni Identification of novel readouts to assess anti-fibrotic efficacy of new compounds in a bleomycin-induced pulmonary fibrosis mouse model
BRPI0610267B8 (pt) métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método
Williams Characterization of muscle tissue in sepsis induced mouse models
Abo-Aziza Advances and prospective in diagnosis of hydatidosis in farm animals

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORA

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/12/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/01/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2809 DE 05-11-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.